Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [ 18f]6-(2-fluoropropyl)-4-methyl-pyridin-2-amine as a potential PET tracer for inducible nitric oxide synthase

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2443-2453

  Zhou, Dong ^a   Lee, Hsiaoju ^a   Rothfuss, Justin M ^a   Chen, Delphine L ^a   Ponde, Datta E ^a,b   Welch, Michael J ^a   Mach, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2 FLUOROPROPYL) 4 METHYLPYRIDIN 2 AMINE F 18; 6 (3 FLUOROPROPYL) 4 METHYLPYRIDIN 2 AMINE; 6 (4 FLUOROBUTYL) 4 METHYLPYRIDIN 2 AMINE; ACTIN; AMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PICOLINE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVATION; IC 50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

AMINOPYRIDINES; ANIMALS; DRUG DESIGN; ENZYME ACTIVATION; FLUORINE RADIOISOTOPES; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 65249117571     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801556h     Document Type: Article

References (45)

1. For the latest reviews, see: (a) Mollace, V.; Muscoli, C.; Masini, E.; Cuzzocrea, S.; Salvemini, D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev. 2005, 57 , 217-252.
2. (b) Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001, 357 , 593-615.
3. (a) Stuehr, D. J. Mammalian nitric oxide synthases. Biochim. Biophys. Acta 1999, 1411 , 217-230.
4. (b) Marietta, M. A. Nitric oxide synthase structure and mechanism. J. Biol. Chem. 1993, 268 , 12231-12234.
5. (a) Marietta, M. A.; Hurshman, A. R.; Rusche, K. M. Catalysis by nitric oxide synthase. Curr. Opin. Chem. Biol. 1998, 2 , 656-663.
6. (b) Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001, 357 , 593-615.
7. Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992, 6 , 3051-3064.
8. (a) Titheradge, M. A. Nitric oxide in septic shock. Biochim. Biophys. Acta 1999, 1411 , 437-455.
9. (b) Hobbs, A. J.; Higgs, A.; Moncada, S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol. 1999, 39 , 191-220.
10. (c) Vallance, P.; Leiper, J. Blocking NO synthesis: how, where and why? Nat. Rev. Drug Discovery 2002, 1 , 939-950.
11. (d) Moore, D. J.; West, A. B.; Dawson, V. L.; Dawson, T. M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 2005, 28 , 57-87.
12. (e) Li, H.; Förstermann, U. Nitric oxide in the pathogenesis of vascular disease. J. Pathol. 2000, 190, 244-254.
13. (f) Xu, W.; Liu, L. Z.; Loizidou, M.; Ahmed, M.; Charles, I. G. The role of nitric oxide in cancer. Cell Res. 2002, 12 , 311-320.
14. Lechner, M.; Lirk, P.; Rieder, J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin. Cancer Biol. 2005, 15 , 277-289.
15. (a) Narayanan, K.; Spack, L.; McMillan, K.; Kilbourn, R. G.; Hayward, M. A.; Masters, B. S.; Griffith, O. W. S -Alkvl-L-thiocitrullines. Potent stereoselective inhibitors of nitric oxide svnthase with strong pressor activity in vivo. J. Biol. Chem. 1995, 270 , 11103-11110.
16. (b) Moore, W. M.; Webber, R. K.; Jerome, G. M.; Tjoeng, F. S.; Misko, T. P.; Currie, M. G. L-N6 - (Iminoethyl) lysine:a selective inhibitor of inducible nitric oxide synthase. J. Med. Chem. 1994, 37 , 3886-3888.
17. (c) Moore, W. M.; Webber, R. K.; Fok, K. F.; Jerome, G. M.; Connor, J. R.; Manning, P. T.; Wyatt, P. S.; Misko, T. P.; Tjoeng, F. S.; Currie, M. G. 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J1. Med. Chem. 1996, 39 , 669-672.
18. (d) McCall, T. B.; Feelisch, M.; Palmer, R. M.; Moncada, S. Identification of N -iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells. Br. J. Pharmacol. 1991, 102 , 234-238.
19. (e) Furfine, E. S.; Harmon, M. F.; Paith, J. E.; Knowles, R. G.; Salter, M.; Kiff, R. J.; Duffy, C.; Hazelwood, R.; Oplinger, J. A.; Garvey, E. P. Potent and selective inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide synthase by S -methyl-L-thiocitruHine and S -ethyl- L-thiocitrulline. J. Biol. Chem. 1994, 269 , 26677-26683.
20. (f) Narayanan, K.; Spack, L.; McMillan, K.; Kilbourn, R. G.; Hayward, M. A.; Masters, B. S.; Griffith, O. W. S -Alkvl-L-thiocitrullines. Potent stereoselective inhibitors of nitric oxide synthase with strong pressor activity in vivo. J. Biol. Chem. 1995, 270 , 11103-11110.
21. (g) Southan, G. J.; Szabo, C.; Thiemermann, C. Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br. J. Pharmacol. 1995, 114 , 510-516.
22. (a) Young, R. J.; Beams, R. M.; Carter, K.; Clark, H. A.; Coe, D. M.; Chambers, C. L.; Davies, P. I.; Dawson, J.; Drysdale, M. J.; Franzman, K. W.; French, C.; Hodgson, S. T.; Hodson, H. F.; Kleanthous, S.; Rider, P.; Sanders, D.; Sawyer, D. A.; Scott, K. J.; Shearer, B. G.; Stacker, R.; Smith, S.; Tackley, M. C.; Knowles, R. G. Inhibition of inducible nitric oxide synthase by acetamidine derivatives of heterosubstituted lysine and homolysine. Bioogs. Med. Chem. Lett. 2000, 10, 597-600.
23. (b) Garvey, E. P.; Oplinger, J. A.; Furfine, E. S.; Kiff, R. J.; Laszlo, F.; Whittle, B. J.; Knowles, R. G. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J. Biol. Chem. 1997, 272 , 4959-4963.
24. (c) Strub, A.; Ulrich, W. R.; Hesslinger, C.; Eltze, M.; Fuchss, T.; Strassner, J.; Strand, S.; Lehner, M. D.; Boer, R. The novel imidazopyridine 2-[2- (4-methoxy-pyridin-2-yl) -ethyrj-3H -imidazo[4, 5-b ]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric oxide synthase. Mol. Pharmacol. 2006, 69 , 328-337.
25. (d) Beaton, H.; Hamley, P.; Nicholls, D. J.; Tinker, A. C.; Wallace, A. V. 3, 4- Dihydro-1-isoquinolinamines: a novel class of nitric oxide synthase inhibitors with a range of isoform selectivity and potency. Bioorg. Med. Chem. Lett. 2001, 11 , 1023-1026.
26. (e) Naka, M.; Nanbu, T.; Kobayashi, K.; Kamanaka, Y.; Komeno, M.; Yanase, R.; Fukutomi, T.; Fujimura, S.; Seo, H. G.; Fujiwara, N.; Ohuchida, S.; Suzuki, K.; Kondo, K.; Taniguchi, N. A potent inhibitor of inducible nitric oxide synthase, ONO-1714, a cyclic amidine derivative. Biochem. Biophys. Res. Commun. 2000, 270 , 663-667.
27. (a) Faraci, W. S.; Nagel, A. A.; Verdries, K. A.; Vincent, L. A.; Xu, H.; Nichols, L. E.; Labasi, J. M.; Salter, E. D.; Pettipher, E. R. 2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo. Br. J. Pharmacol. 1996, 119 , 1101-1108.
28. (b) Pettipher, E. R.; Hibbs, T. A.; Smith, M. A.; Griffiths, R. J. Analgesic activity of 2-amino-4-methylpyridine, a novel NO synthase inhibitor. Inflamm. Res. 1997, 46 , S135-S136.
29. Hagmann, W. K.; Caldwell, C. G.; Chen, P.; Durette, P. L.; Esser, C. K.; Lanza, T. J.; Kopka, I. E.; Guthikonda, R.; Shah, S. K.; MacCoss, M.; Chabin, R. M.; Fletcher, D.; Grant, S. K.; Green, B. G.; Humes, J. L.; Kelly, T. M.; Luell, S.; Meurer, R.; Moore, V.; Pacholok, S. G.; Pavia, T.; Williams, H. R.; Wong, K. K. Substituted 2-aminopyridines as inhibitors of nitric oxide synthases. Bioorg. Med. Chem. Lett. 2000, 10 , 1975-1978.
30. Connolly, S.; Aberg, A.; Arvai, A.; Beaton, H. G.; Cheshire, D. R.; Cook, A. R.; Cooper, S.; Cox, D.; Hamley, P.; Mallinder, P.; Millichip, I.; Nicholls, D. J.; Rosenfeld, R. J.; St-Gallay, S. A.; Tainer, J.; Tinker, A. C.; Wallace, A. V. 2-Aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution. J. Med. Chem. 2004, 47 , 3320-3323.
31. 183pF]fluoroethyl) isothiourea, as potential positron emission tomography tracers. J. Med. Chem. 1996, 39 , 5110-5118.
32. 18F]FFDI), a potential PET radiotracer for the inducible nitric oxide synthase. Curr. Radiopharm. 2008, 1, 49-53.
33. (c) de Vries, E. F.; Vroegh, J.; Dijkstra, G.; Moshage, H.; Elsinga, P. H.; Jansen, P. L.; Vaalburg, W. Synthesis and evaluation of a fluorine-18 labeled antisense oligonucleotide as a potential PET tracer for iNOS mRNA expression. Nucl. Med. Biol. 2004, 31 , 605-612.
34. Peterson, D. J. Carbonyl olefination reaction using silyl-substituted organomet al.lic compounds. J. Org. Chem. 1968, 33 , 780-784.
35. Bryk, R.; Wolff, D. J. Pharmacological modulation of nitric oxide synthesis by mechanism-based inactivators and related inhibitors. Pharmacol. Ther. 1999, 84 , 157-178.
36. Tiso, M.; Strub, A.; Hesslinger, C.; Kenney, C. T.; Boer, R.; Stuehr, D. J. BYK191023 (2-[2- (4-methoxy-pyridin-2-yl) -ethyl]-3h -imidazo[4, 5- b ]pyridine) is an NADPH- and time-dependent irreversible inhibitor of inducible nitric-oxide synthase. Mol. Pharmacol. 2008, 73 , 1244- 1253.
37. Speyer, C. L.; Neff, T. A.; Warner, R. L.; Guo, R. F.; Sarma, J. V.; Riedemann, N. C.; Murphy, M. E.; Murphy, H. S.; Ward, P. A. Regulatory effects of iNOS on acute lung inflammatory responses in mice. Am. J. Pathol. 2003, 163 , 2319-2328. (a) Liu, S. F.; Adcock, I. M.; Old, R. W.; Barnes, P. J.; Evans, T. W. Differential regulation of the constitutive and inducible nitric oxide synthase mRNA by lipopolysaccharide treatment in vivo in the rat. Crit. Care Med. 1996, 24 , 1219-1225.
38. (b) Buttery, L. D.; Evans, T. J.; Springall, D. R.; Carpenter, A.; Cohen, J.; Polak, J. M. Immunochemical localization of inducible nitric oxide synthase in endotoxin-treated rats. Lab Invest. 1994, 7 , 755-764.
39. (c) Kan, W.; Zhao, K. S.; Jiang, Y.; Yan, W.; Huang, Q.; Wang, J.; Qin, Q.; Huang, X.; Wang, S. Lung, spleen, and kidney are the major places for inducible nitric oxide synthase expression in endotoxic shock: role of p38 mitogen-activated protein kinase in signal transduction of inducible nitric oxide synthase expression. Shock 2004, 21 , 281-287.
40. Moncada, S.; Higgs, E. A. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995, 9 , 1319-1330.
41. (a) Kovách, A. G.; Szabó, C.; Benyó, Z.; Csáki, C.; Greenberg, J. H.; Reivich, M. Effects of NG-nitro-L-arginine and L-arginine on regional cerebral blood flow in the cat. J. Physiol. 1992, 449 , 183-196.
42. (b) Benyó, Z.; Kiss, G.; Szabó, C.; Csáki, C.; Kovách, A. G. Importance of basal nitric oxide synthesis in regulation of myocardial blood flow. Cardiouasc. Res. 1991, 25 , 700-703.
43. (c) Gardiner, S. M.; Compton, A. M.; Bennett, T.; Palmer, R. M.; Moncada, S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990, 15 , 486-492.
44. Alderton, W. K.; Angell, A. D.; Craig, C.; Dawson, J.; Garvey, E.; Moncada, S.; Monkhouse, J.; Rees, D.; Russel, R. J.; Schwartz, S.; Waslidge, N.; Knowles, R. G. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 2005, 145 , 301-312.
45. Newman, Melvin, S.; Waltcher, I.; Ginsberg, H. F. The synthesis and reduction of some polyfunctional acetylene compounds. J. Org. Chem. 1952, 17 , 962-970.